Dogwood Therapeutics (DWTX) Competitors $6.05 -0.42 (-6.49%) Closing price 04:00 PM EasternExtended Trading$6.10 +0.06 (+0.91%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsBuy This Stock DWTX vs. SNYR, ELEV, PULM, TNXP, MRNS, IRD, VRCA, UBX, AKTX, and GDTCShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Synergy CHC Corp. (Uplisting) (SNYR), Elevation Oncology (ELEV), Pulmatrix (PULM), Tonix Pharmaceuticals (TNXP), Marinus Pharmaceuticals (MRNS), Opus Genetics (IRD), Verrica Pharmaceuticals (VRCA), Unity Biotechnology (UBX), Akari Therapeutics (AKTX), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Synergy CHC Corp. (Uplisting) Elevation Oncology Pulmatrix Tonix Pharmaceuticals Marinus Pharmaceuticals Opus Genetics Verrica Pharmaceuticals Unity Biotechnology Akari Therapeutics CytoMed Therapeutics Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Do analysts rate SNYR or DWTX? Synergy CHC Corp. (Uplisting) currently has a consensus price target of $10.00, indicating a potential upside of 227.87%. Given Synergy CHC Corp. (Uplisting)'s stronger consensus rating and higher probable upside, research analysts clearly believe Synergy CHC Corp. (Uplisting) is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of SNYR or DWTX? 9.1% of Dogwood Therapeutics shares are held by institutional investors. 12.2% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in SNYR or DWTX? Synergy CHC Corp. (Uplisting) received 2 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSynergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% Dogwood TherapeuticsN/AN/A Does the media refer more to SNYR or DWTX? In the previous week, Dogwood Therapeutics had 4 more articles in the media than Synergy CHC Corp. (Uplisting). MarketBeat recorded 6 mentions for Dogwood Therapeutics and 2 mentions for Synergy CHC Corp. (Uplisting). Dogwood Therapeutics' average media sentiment score of 0.66 beat Synergy CHC Corp. (Uplisting)'s score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC Corp. (Uplisting) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SNYR or DWTX more profitable? Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat Dogwood Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC Corp. (Uplisting)N/A N/A N/A Dogwood Therapeutics N/A -217.12%-172.06% Which has higher earnings & valuation, SNYR or DWTX? Synergy CHC Corp. (Uplisting) has higher revenue and earnings than Dogwood Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC Corp. (Uplisting)$26.01M1.02N/AN/AN/ADogwood TherapeuticsN/AN/A-$5.30M-$6.55-0.92 SummarySynergy CHC Corp. (Uplisting) beats Dogwood Therapeutics on 8 of the 12 factors compared between the two stocks. Remove Ads Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.06M$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.927.2324.5819.25Price / SalesN/A230.75395.7394.10Price / CashN/A65.6738.1634.64Price / Book1.226.617.064.46Net Income-$5.30M$142.13M$3.20B$247.07M7 Day Performance6.70%2.79%1.49%3.06%1 Month Performance20.76%2.68%5.87%-2.85%1 Year PerformanceN/A-4.41%14.97%4.64% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood TherapeuticsN/A$6.05-6.5%N/AN/A$8.06MN/A-0.925Upcoming EarningsSNYRSynergy CHC Corp. (Uplisting)2.8684 of 5 stars$3.58+0.8%$10.00+179.3%N/A$31.16M$26.01M0.0040ELEVElevation Oncology2.4535 of 5 stars$0.53-1.3%$6.83+1,199.4%-93.6%$31.14MN/A-0.6440Analyst ForecastAnalyst RevisionNews CoverageGap UpPULMPulmatrix0.3969 of 5 stars$8.39-0.8%N/A+328.7%$30.62M$10.01M-3.1820Earnings ReportUpcoming EarningsNews CoveragePositive NewsTNXPTonix Pharmaceuticals2.2654 of 5 stars$16.28+8.5%$1,100.00+6,656.8%-97.2%$30.43M$11.29M0.0050Earnings ReportNews CoverageGap UpMRNSMarinus Pharmaceuticals2.3557 of 5 stars$0.55-0.2%$4.79+771.6%-93.8%$30.32M$30.99M-0.22110News CoverageIRDOpus Genetics2.8743 of 5 stars$0.94+0.7%$8.00+749.6%N/A$29.72M$8.38M-0.8614Upcoming EarningsVRCAVerrica Pharmaceuticals3.8537 of 5 stars$0.65+21.1%$9.50+1,360.4%-89.6%$29.66M$7.57M-0.3640Negative NewsUBXUnity Biotechnology4.2054 of 5 stars$1.75-1.1%$7.33+319.0%-17.2%$29.52M$240,000.00-1.3460Analyst ForecastNews CoverageAKTXAkari TherapeuticsN/A$1.10+1.9%N/A-19.9%$29.25MN/A0.009Upcoming EarningsGDTCCytoMed Therapeutics2.4487 of 5 stars$2.65+6.9%$5.00+88.7%+16.8%$28.99MN/A0.00N/APositive News Remove Ads Related Companies and Tools Related Companies SNYR Alternatives ELEV Alternatives PULM Alternatives TNXP Alternatives MRNS Alternatives IRD Alternatives VRCA Alternatives UBX Alternatives AKTX Alternatives GDTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DWTX Stock Free DWTX Stock Alerts